Mesenchymal Stem Cell Transplantation for Heart Failure

"This clinical trial seeks to enroll 72 individuals with heart failure whose ages are between 18 and 80. The eligibility criteria for this study is as follows: patients must have a left ventricular ejection fraction of 40% or less due to treatment with anthracyclines, be able to perform the six-minute walk test, been treated with maximal medical therapy for heart failure, not had trastuzumab in the past 90 days if they did receive it previously, and sign an informed consent form from either themselves or their legal representative."

"Considering the limited data available on Mesenchymal Stem Cell Transplantation, our team at Power has deemed it to be relatively low risk and thus gave it a score of 1."

"The primary outcome monitored from Baseline to 6 months is the Incidence of adverse events. Other secondary outcomes tracked include Aborted death due to an Automatic Implantable Cardioverter Defibrillator (AICD) firing, Revascularization requirements, and Change in improvement of left ventricular systolic function as assessed by Left Ventricular Ejection Fraction (LVEF). Statistical analyses will be displayed via tables with confidence intervals of differences between investigational groups and control group; if significant at p < .05 level, then a gatekeeping procedure can compare two drugs using two-sample t-tests without adjustments for"

"This medical experiment is seeking volunteers who are of legal age and under the octogenarian threshold."

"That is correct. According to clinicaltrials.gov, the original posting for this trial was on July 18th 2020 and it has since been updated as recently as November 16th 2022. The study aims to recruit 72 patients from a single centre."

"Yes, the details on clinicaltrials.gov affirms that this research is currently in search of volunteers. It was first published on July 18th 2020 and was revised lastly on November 16th 2022. 72 people will be required to take part at one site."